History shows investors should stick to profitable companies if Fed tightens inflation action, Jim Cramer says

History shows investors should stick to profitable companies if Fed tightens inflation action, Jim Cramer says


CNBC’s Jim Cramer on Thursday advised investors to invest in profitable companies if the Federal Reserve institutes a half-point double rate hike, using an analysis of the Fed’s last double rate hike and its aftermath in 2000.

“We know what works when the Fed tightens aggressively. The lesson of 2000 is to stick with profitable companies with real products or services that also have meaningful dividends and buybacks, and to sell the rest,” he said.

The “Mad Money” host’s comments come after traders predicted half-point rate hikes in May and June in response to Federal Reserve Chairman Jay Powell’s pledge on Monday to take strong action against surging inflation.

The Dow Jones Industrial Average rose 1% on Thursday while the S&P 500 gained 1.4%. The Nasdaq Composite climbed 1.9%.

Cramer noted that when then Fed Chair Alan Greenspan implemented a double rate hike in May 2020, the dotcom bubble had burst two months earlier. The Fed had already raised interest rates five times over the previous 11 months, with the May interest rate concluding the tightening cycle, he said.

The Nasdaq lost 78% of its value from its peak in March of that year to October 2002, with 60% of the loss happening after Greenspan implemented a double rate hike, according to Cramer. The S&P 500 fell 50% from its peak with almost 90% of its decline coming after the rate hike while the Dow Jones Industrial Average went down 39% from its high with 80% of the decrease coming after the hike, Cramer said.

Some winners included healthcare, energy and financial stocks, while tech stocks plummeted due to the burst of the dotcom bubble, he added.

However, the host reminded viewers that there are outside factors that make both the current markets and the markets in 2000 unique and not directly comparable, including the current Russia-Ukraine war and the recession in the early 2000s.

“I don’t think we’re watching a one-to-one replay of the dotcom collapse. … But it wouldn’t surprise me if the averages experience more pain between now and the next Fed meeting in early May, especially the unprofitable companies in the tech-heavy Nasdaq,” he said.

Sign up now for the CNBC Investing Club to follow Jim Cramer’s every move in the market.

Disclaimer

Questions for Cramer?
Call Cramer: 1-800-743-CNBC

Want to take a deep dive into Cramer’s world? Hit him up!
Mad Money TwitterJim Cramer Twitter – Facebook – Instagram

Questions, comments, suggestions for the “Mad Money” website? [email protected]





Source

Inside the booming business of wellness third spaces and membership clubs
Business

Inside the booming business of wellness third spaces and membership clubs

A few years ago, Grace Guo began to crave places in New York City where hanging out with friends didn’t have to involve alcohol. Newly sober and surrounded by friends who also chose not to drink, Guo said she wanted alternatives to the typical social scene. After some research, she landed on Bathhouse and Othership: […]

Read More
FDA vaccine head will step down in April after string of controversial decisions
Business

FDA vaccine head will step down in April after string of controversial decisions

The logo for the Food and Drug Administration is seen ahead of a news conference at the Health and Human Services Headquarters in Washington, DC on April 22, 2025. Nathan Posner | Anadolu | Getty Images A key U.S. Food and Drug Administration official who oversees vaccines and biotech treatments will step down from the […]

Read More
FDA reversals leave investors worrying about the fates of other experimental drugs
Business

FDA reversals leave investors worrying about the fates of other experimental drugs

Investors are concerned about the fates of multiple experimental drugs for hard-to-treat diseases following a string of recent rejections from the U.S. Food and Drug Administration.  The FDA in the past year has denied or discouraged the applications of at least eight drugs, according to RTW Investments, including a gene therapy for Huntington’s disease from […]

Read More